Clinical Trials List
2020-01-01 - 2025-12-31
Phase II
Recruiting1
Terminated2
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Single Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 林宗哲 Division of Hematology & Oncology
- 吳志宏 Division of Radiology
- Ann-Lii Cheng Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- Jia-Horng Kao Division of General Internal Medicine
- Chiun Hsu Division of Hematology & Oncology
- TSUNG-HAO LIU Division of Hematology & Oncology
- 曾岱宗 Division of General Internal Medicine
- Chih-Hung Hsu Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- BANG-BIN CHEN Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳宗哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 陳柏邑 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
30 participants
